To crack the code of FSHD, patients are absolutely essential
All of the breakthroughs—the discovery of the genetic causes, understanding why some patients vary so greatly in the severity of their symptoms, teasing out the biochemical pathways that could point to future treatments—were made because patients stepped up to the plate.
Too often, we hear patients say they’ll volunteer when there’s a treatment. But we will never get to a treatment unless patients participate in fundamental research now. FSHD is uniquely human, so no laboratory mouse can ever fully model the disease. The genetic “package” that causes FSHD is found only in people. We owe an enormous debt to the patients who give DNA samples. Who submit to long interviews and exhausting physical tests. Allow a surgeon to cut out a small muscle sample. Who fight claustrophobia to lie in the narrow bore of an MRI machine.
Equally important are patients’ family members, both affected and unaffected, who provide the best experimental controls because of their shared genetic and environmental backgrounds. A parent or sibling who has very mild symptoms may hold the key to understanding the factors that protect against the full-blown development of FSHD symptoms in a more severely affected family member.
We are more hopeful today than ever before that a treatment is within sight. We cannot guarantee when that treatment will arrive, but here’s one thing we guarantee: If you volunteer for research, your participation will without question help move us a step closer to that day.
Scientific Overview of FSHD
Read the latest on wikipedia
Glossary of Scientific Terms
The FACT Alliance
Progress through collaboration by Jamshid Arjomand, PhD, Chief Science Officer As a fan of home improvement shows, I’m fascinated by the evolution of going from an idealized dream home or… Read More »
2023 International Research Congress summary
The journal Neuromuscular Disease has published a summary of the FSHD Society’s 2023 scientific conference held in Milan, Italy, this past June. The article was co-authored by Jamshid Arjomand, PhD,… Read More »
A holistic approach
What the FSHD Society can and must do for the community by June Kinoshita, FSHD Society The FSHD Society has been tightly focused on understanding FSHD and speeding up the… Read More »
Orphan drug designation for Epic Bio’s FSHD candidate
Read the full news release here. SOUTH SAN FRANCISCO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas… Read More »